用于酒精使用障碍的微生物群-肠道-脑轴中小分子的治疗策略。
Therapeutic strategies of small molecules in the microbiota-gut-brain axis for alcohol use disorder.
机构信息
Departments of Neurosurgery, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA; Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan 610075, China.
Section of Molecular Pharmacology and Toxicology, National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Rockville, MD 20892, USA.
出版信息
Drug Discov Today. 2023 May;28(5):103552. doi: 10.1016/j.drudis.2023.103552. Epub 2023 Mar 11.
The microbiota-gut-brain axis (MGBA) is important in maintaining the structure and function of the central nervous system (CNS) and is regulated by the CNS environment and signals from the peripheral tissues. However, the mechanism and function of the MGBA in alcohol use disorder (AUD) are still not completely understood. In this review, we investigate the underlying mechanisms involved in the onset of AUD and/or associated neuronal deficits and create a foundation for better treatment (and prevention) strategies. We summarize recent reports focusing on the alteration of the MGBA in AUD. Importantly, we highlight the properties of small-molecule short-chain fatty acids (SCFAs), neurotransmitters, hormones, and peptides in the MGBA and discusses their usage as therapeutic agents against AUD.
肠道微生物-肠-脑轴（MGBA）在维持中枢神经系统（CNS）的结构和功能方面很重要，并且受到 CNS 环境和来自外周组织的信号的调节。然而，MGBA 在酒精使用障碍（AUD）中的机制和功能仍不完全清楚。在这篇综述中，我们研究了 AUD 发病和/或相关神经元缺陷的潜在机制，并为更好的治疗（和预防）策略奠定了基础。我们总结了最近关于 AUD 中 MGBA 改变的报告。重要的是，我们强调了 MGBA 中小分子短链脂肪酸（SCFAs）、神经递质、激素和肽的特性，并讨论了它们作为治疗 AUD 的治疗剂的用途。
Zotero 插件